HIKMA Pharmaceuticals PLC — Director's Dealing 2016

Mar 17, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4832S

Hikma Pharmaceuticals Plc

17 March 2016

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 17 March 2016: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the Remuneration Committee has made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Awards under the EIP were made on 17 March 2016 at a price of 1,815 pence per Ordinary Share (being the closing price the day before grant) as follows:

PDMR	Element B Shares	Element C Shares
Said Darwazah	68,346	45,100
Mazen Darwazah	38,501	25,406
Bassam Kanaan	26,090	26,090
Majda Labadi	14,530	14,530
Riad Mishlawi	19,890	19,890
Khalid Nabulsi	20,400	20,400
Mike Raya	29,484	29,484
Susan Ringdal	15,730	15,730

The Element B share awards will be released to the participants in two years from the date of grant subject to their continued employment and the non-occurrence of forfeiture events during the vesting period as judged by the Remuneration Committee at each anniversary of the grant.

The Element C share awards will be released to the participants in three years from the date of grant subject to their continued employment.

These participants are must retain 50% of the vested shares under elements B and C until five years from the date of grant.

Further details on the EIP, forfeiture criteria and holding period can be found in Hikma's report and accounts for the year ended 31 December 2014 on pages 98, 103 and 104.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC         

Peter Speirs                                                                       +44 20 7399 2760

Company Secretary

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBUGDXXDBBGLR